top of page

Alto Neuroscience's CEO on why MDD data at #ACNP2023 may validate its precision medicine approach

Amit Etkin says that psychiatric conditions have been treated too broadly in the past and explains how Alto is using computing power to recognize, define, and treat subpopulations within diseases.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page